In a recent Form 13F filing with the Securities & Exchange Commission, Citigroup Inc. revealed that it has significantly increased its stake in Syneos Health, Inc. (NASDAQ:SYNH). According to the filing, Citigroup’s holdings in the company rose by an astonishing 1,293.5% during the first quarter of this year.
The financial institution now owns a total of 455,940 shares of Syneos Health, after purchasing an additional 423,221 shares during the quarter. This represents approximately 0.44% of the healthcare services provider’s outstanding stock. The total value of Citigroup’s investment in Syneos Health amounts to $16,241,000 as of the end of the reporting period.
Syneos Health is a leading clinical research organization that provides pharmaceutical companies with integrated solutions for their drug development and commercialization needs. The company operates in various segments, including Clinical Solutions and Commercial Solutions.
Investors who are interested in seeing what other hedge funds hold positions in Syneos Health can visit HoldingsChannel.com. This website offers up-to-date information on 13F filings and insider trades for a range of stocks, including SYNH.
Several equities research analysts have recently commented on Syneos Health’s performance and prospects. For instance, StockNews.com issued a “hold” rating for the company in a report published on August 22nd. Barclays also upgraded their rating for Syneos Health from “underweight” to “equal weight” on May 10th.
On May 11th, Robert W. Baird downgraded their recommendation for Syneos Health from “outperform” to “neutral.” Similarly, Deutsche Bank Aktiengesellschaft shifted their rating from “buy” to “hold” on that same day. Mizuho analysts raised their price target for SYNH from $38.00 to $43.00 in a report released on May 16th.
According to Bloomberg, a total of nine investment analysts currently rate the stock as “Hold.” The consensus price target for Syneos Health is set at $44.00.
It remains to be seen how the increased ownership by Citigroup will impact the future performance of Syneos Health and whether other institutions will follow suit. Investors should closely monitor any developments regarding this holding and consider them when making investment decisions.
Institutional Investors Show Confidence in Syneos Health, Inc. as Stock Attracts Attention
Syneos Health, Inc., a prominent integrated biopharmaceutical solutions company, has attracted the attention of several institutional investors in recent times. Among them, OLD Mission Capital LLC acquired a new position in the company during the fourth quarter, worth approximately $31,000. Similarly, Mesirow Institutional Investment Management Inc. also acquired a new position during the first quarter, amounting to around $38,000.
Meanwhile, China Universal Asset Management Co. Ltd. has shown significant interest in Syneos Health by increasing its position in the company by 33.9% during the first quarter. The firm now owns 1,399 shares of Syneos Health’s stock valued at $50,000 after purchasing an additional 354 shares in the last quarter.
In addition to that, CWM LLC witnessed a notable surge of 122.9% in its position in Syneos Health during the fourth quarter. The firm now holds 1,413 shares of the company’s stock valued at $52,000 after acquiring an additional 779 shares last quarter.
Lastly,Lazard Asset Management LLC decided to acquire a new position in Syneos Health during the first quarter for approximately $53,000.
These actions taken by various institutional investors reflect their confidence and belief in Syneos Health’s potential for growth and success.
It is worth mentioning that institutional investors and hedge funds currently own approximately 91.16% of the company’s stock. This suggests a high level of trust placed on Syneos Health’s future prospects.
Moving on from this financial news surrounding institutional investments, let us take a look at how Syneos Health has performed on NASDAQ SYNH recently.
On Tuesday, August 29th (reference date), NASDAQ SYNH opened at $42.54 per share. The business has maintained a fifty-day moving average price of $42.33 and a two-hundred-day moving average price of $40.03.
Syneos Health, Inc. also has a debt-to-equity ratio of 0.77, indicating a balanced level of financial stability. In terms of liquidity, the company boasts a current ratio and quick ratio of 1.20 each, further strengthening its position in the market.
However, it is important to note that Syneos Health’s fifty-two week low stood at $22.89 while its fifty-two week high reached $64.25 during the same period.
With these figures in view, Syneos Health holds a market capitalization of $4.41 billion alongside a price-earnings (PE) ratio of 61.65 and a beta score of 1.58.
For those interested in exploring other hedge funds’ positions in Syneos Health, HoldingsChannel.com provides updated information on 13F filings and insider trades related to the company’s stock under the NASDAQ:SYNH ticker symbol.
In conclusion, Syneos Health continues to be an intriguing prospect for institutional investors due to its integrated biopharmaceutical solutions offerings and solid financial standing. As it operates through two segments – Clinical Solutions and Commercial Solutions – it covers various aspects of clinical development and brings value through innovative diagnostics, drugs, biologics, devices, and digital therapeutics from Phase I to IV.
For more comprehensive insights into Syneos Health’s recent developments and prospects for growth, interested parties are encouraged to review the latest report available on their official website or reach out for detailed analysis from industry experts.
Source: beststocks.com
